When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis
Authors: William C. Becker, David A. Fiellin
Journal: Annals of Internal Medicine (2020)

Ideas and Opinions2 April 2020When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid CrisisFREEWilliam C. Becker, MD and David A. Fiellin, MDWilliam C. Becker, MDVA Connecticut Healthcare System, West Haven, Connecticut, and Yale Program in Addiction Medicine and Yale School of Medicine, New Haven, Connecticut (W.C.B.)Search for more papers by this author and David A. Fiellin, MDYale Program in Addiction Medicine and Yale School of Medicine, New Haven, Connecticut (D.A.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-1210 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail With the coronavirus disease 2019 (COVID-19) pandemic projected to be the largest mass casualty event in U.S. history, large-scale efforts are under way to contain the spread through social distancing and to divert resources to acute care. Before the first COVID-19 case in the United States, a different epidemic—the opioid crisis—was taking the lives of 130 Americans per day (1). Given that infection epidemics disproportionately affect socially marginalized persons with medical and psychiatric comorbid conditions—characteristics of those with opioid use disorder (OUD)—we are gravely concerned that COVID-19 will increase already catastrophic opioid overdose rates. Besides the threat of infection to persons with OUD, there is serious risk that system-level gains in expanding access to medication for OUD, conducting critical research, and exacting legal reparations against opioid manufacturers will all reverse. We call for urgent action to counteract these risks.Treatment systems need to facilitate uninterrupted access to the most effective medications for OUD treatment: methadone and buprenorphine (2). Regarding methadone, federal agencies relaxed requirements for physical examinations and allowed extended medication supply for stable patients (3). We need to rapidly expand methadone delivery via mobile teams (for example, repurposed syringe service programs) for quarantined patients. Opioid treatment programs—federally regulated facilities that primarily dispense methadone—should increase use of buprenorphine because of its safer pharmacologic properties and formulations that can be dosed thrice weekly and monthly. Federal agencies should leverage funds from a recent settlement about misuse of regulatory procedures by a buprenorphine manufacturer (4) to address financial barriers to buprenorphine provided through opioid treatment programs.Buprenorphine prescribers should be allowed and encouraged to engage in all phases of care—evaluation, initiation of therapy, and monitoring—via telemedicine when appropriate. The Drug Enforcement Administration recently took a significant step by permitting teleprescribing of buprenorphine if 2-way audiovisual communication between the prescriber and the patient is in place, allowing for telephone-only communication when needed (5). Given that patients may not have adequate data access plans, we recommend that funding be allocated to support data plans for teleprescribing visits for patients initiating or continuing buprenorphine (and methadone) treatment. In-home initiation of buprenorphine is feasible and safe and is supported by new dose titration protocols that eliminate the need for opioid withdrawal (6).We recommend several additional steps to ensure access to buprenorphine in preparation for shifts in prescribers' work duties or sick leave due to COVID-19 and potential treatment disruptions as patients move in and out of hospitals. The federal government should temporarily remove limits on the number of patients an individual prescriber may treat concurrently. At present, clinicians are limited in the number of patients for whom they can treat concurrently in their first year. For the near future, these limits should be removed. In addition, we recommend that federal, state, and local governments be funded to form and support networks of experienced buprenorphine prescribers to address the needs of local patients and providers. For instance, the mentors from the federally funded Prescriber Clinical Support System, and those identified through primary care, addiction medicine, and addiction psychiatry societies, could be rapidly expanded and authorized to temporarily support clinicians and potentially prescribe for patients in their region if usual prescribers are unavailable. As more patients with OUD are admitted to hospitals, these networks would be available to provide remote consultative services to help reduce length of stay. To help reduce emergency department and hospital crowding, federal training requirements for buprenorphine should be eliminated to allow emergency medicine and hospitalist clinicians without waivers to write buprenorphine prescriptions at discharge to provide enough medication for patients to become engaged in outpatient treatment. Federal and state agencies should ensure that skilled-nursing facilities do not refuse patients receiving methadone or buprenorphine.Beyond day-to-day OUD treatment, COVID-19 threatens to grind essential clinical research to a halt unless proactive steps are taken. During the past 2 years, Congress authorized approximately $1 billion in the HEAL (Helping to End Addiction Long-term) initiative. Much of this work is just starting. In 2019, HEAL funded approximately 375 projects in 41 states, including 4 states as part of the HEALing Communities Study testing a “community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across health care, behavioral health, justice, and other community-based settings” (7). With virtually all research involving face-to-face contact stopping, these results will be delayed and study viability will be threatened. The effect of the COVID-19 pandemic on scientific validity will also need to be considered as the crisis profoundly changes patients and treatment systems. At a minimum, the federal government will need to devise a mechanism to provide ongoing funding for all persons supported to conduct laboratory and clinical research, including those working on opioid-related projects, while projects' safety and scientific validity are considered.Finally, before the COVID-19 pandemic, important strides had been made in compensating victims of opioid manufacturers' malfeasance. For example, in August 2019, the state of Oklahoma won a $572 million lawsuit against Johnson & Johnson, with the judge ruling that the company overstated the benefits and understated the risks of opioid products, thus violating the state's public nuisance laws (8). These monies will go to victims' families and help bolster Oklahoma's addiction treatment resources. Delays in court hearings could backlog 2000 similar lawsuits and significantly delay remuneration, which is especially damaging given the looming economic crisis in the United States. To provide much-needed funding in the midst of these 2 crises, we urge acceleration of cases nearing resolution, a prominent one being Purdue Pharma's bankruptcy case, resolution of which could mean more than $10 billion to families and addiction treatment agencies (9).Persons with OUD are especially vulnerable to not only COVID-19 but also interruptions in life-saving treatment. The response to COVID-19 and the speed with which regulatory barriers are being reconsidered and removed should be translated to opioid-related clinical, research, and legal policy. Bold efforts are needed to reduce the adverse effect that COVID-19 will have on progress in addressing opioid-related morbidity and mortality. In the absence of such efforts, we risk more catastrophic effects from these colliding epidemics.References1. Centers for Disease Control and Prevention. America's drug overdose epidemic: data to action. Accessed at www.cdc.gov/injury/features/prescription-drug-overdose/index.html on 20 March 2020. Google Scholar2. National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. National Academies Pr; 2019. doi:10.17226/25310 CrossrefGoogle Scholar3. Substance Abuse and Mental Health Services Administration. Opioid treatment program (OTP) guidance. Accessed at www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf on 22 March 2020. Google Scholar4. Haffajee RL, Frank RG. Abuses of FDA regulatory procedures—the case of Suboxone. N Engl J Med. 2020;382:496-498. [PMID: 31914238] doi:10.1056/NEJMp1906680 CrossrefMedlineGoogle Scholar5. Drug Enforcement Administration. COVID-19 information page. Accessed at www.deadiversion.usdoj.gov/coronavirus.html on 22 March 2020. Google Scholar6. Becker WC, Frank JW, Edens EL. Switching from high-dose, long-term opioids to buprenorphine: a case series. Ann Intern Med. 2020. [PMID: 32252072]. doi:10.7326/L19-0725 LinkGoogle Scholar7. National Institutes of Health. NIH funds $945 million in research to tackle the national opioid crisis through the NIH HEAL Initiative. Accessed at www.nih.gov/news-events/news-releases/nih-funds-945-million-research-tackle-national-opioid-crisis-through-nih-heal-initiative on 21 March 2020. Google Scholar8. Hoffman J. Johnson & Johnson ordered to pay $572 million in landmark opioid trial. The New York Times. 26 August 2019. Accessed at www.nytimes.com/2019/08/26/health/oklahoma-opioids-johnson-and-johnson.html on 21 March 2020. Google Scholar9. Hals T. U.S. bankruptcy judge warns states not to threaten potential Purdue Pharma settlement. Reuters. 18 March 2020. Accessed at www.reuters.com/article/purdue-pharma-bankruptcy/us-bankruptcy-judge-warns-states-not-to-threaten-potential-purdue-pharma-settlement-idUSL1N2BB3A9 on 21 March 2020. Google Scholar Comments 0 Comments Sign In to Submit A Comment Jon Whitney, PA-CNone6 April 2020 Comment This piece is incorrect: "Advanced practice providers are always limited to 30 patients." I am a PA, and myself as well as NPs are allowed up to 275. Author, Article, and Disclosure InformationAuthors: William C. Becker, MD; David A. Fiellin, MDAffiliations: VA Connecticut Healthcare System, West Haven, Connecticut, and Yale Program in Addiction Medicine and Yale School of Medicine, New Haven, Connecticut (W.C.B.)Yale Program in Addiction Medicine and Yale School of Medicine, New Haven, Connecticut (D.A.F.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-1210.Corresponding Author: William C. Becker, MD, VA Connecticut Healthcare System, Mail Stop 151B, 950 Campbell Avenue, West Haven, CT 06516; e-mail, william.becker@yale.edu.Correction: This article was corrected on 21 April 2020 to correct the statement about the limits on the number of patients an individual prescriber may treat concurrently.Current Author Addresses: Dr. Becker: VA Connecticut Healthcare System, Mail Stop 151B, 950 Campbell Avenue, West Haven, CT 06516.Dr. Fiellin: Yale Program in Addiction Medicine, 367 Cedar Street, New Haven, CT 06510.Author Contributions: Conception and design: D.A. Fiellin.Drafting of the article: W.C. Becker, D.A. FiellinCritical revision of the article for important intellectual content: W.C. Becker, D.A. Fiellin.Final approval of the article: W.C. Becker, D.A. Fiellin.This article was published at Annals.org on 2 April 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCollision of the COVID-19 and Addiction Epidemics Nora D. Volkow An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19 G. Caleb Alexander , Kenneth B. Stoller , Rebecca L. Haffajee , and Brendan Saloner Metrics Cited byPatient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven surveyPhysician perspectives on chronic pain management: barriers and the use of eHealth in the COVID-19 eraInterrupted time series analysis of drug overdose fatalities in service-related industries versus non-service-related industries during the COVID-19 pandemic, 2018–2021COVID-19 and musculoskeletal pain: an overview of the current knowledgePatient Engagement in and Adaptations to Delivery of Outpatient Care for Opioid Use Disorder During the COVID-19 PandemicTrends in Non-Fatal and Fatal Opioid Overdoses During the First Two Years of the Coronavirus Disease-2019 PandemicThe impact of syringe decriminalization within the Pennsylvania harm reduction communityIntegrating Text Messaging in a Low Threshold Telebuprenorphine Program for New York City Residents with Opioid Use Disorder during COVID-19: A Pilot Randomized Controlled TrialAssociation of Medication-Assisted Therapy and Risk of Drug Overdose-Related Hospitalization or Emergency Room Visits in Patients With Opioid Use DisorderMethamphetamine use and illicit opioid use during buprenorphine treatmentZoom-Based Mindfulness-Oriented Recovery Enhancement Plus Just-in-Time Mindfulness Practice Triggered by Wearable Sensors for Opioid Craving and Chronic PainPrevalence and Correlates of Opioid-Involved Suicides in MarylandRates and Correlates of Alcohol and Substance Use Among Women Veterans During the COVID-19 Pandemic: The Moderating Role of COVID-Specific AnxietyPublic Opinion about America’s Opioid Crisis: Severity, Sources, and Solutions in ContextA patient-centered nurse-supported primary care-based collaborative care program to treat opioid use disorder and depression: Design and protocol for the MI-CARE randomized controlled trialPharmacist‐delivered comprehensive medication management in a substance use disorder clinic, an 18‐month descriptive studyA counterfactual analysis of opioid-involved deaths during the COVID-19 pandemic using a spatiotemporal random forest modeling approachLeveraging Randomized Controlled Trial Design: HIV and Wellness Interventions with Marginalized PopulationsChanging Trends in Drug Overdose Mortality in Kentucky: An Examination of Race and Ethnicity, Age, and Contributing Drugs, 2016-2020Implementation and Evaluation of Primary Care Team Participation in Opioid Use Disorder Learning SessionsPeople engaged in opioid agonist treatment as a counterpublic during the COVID ‐19 pandemic in Australia: A qualitative studyIdentifying Patient Characteristics Associated With Opioid Use to Inform Surgical Pain ManagementEvidence-Based Orthopaedic Post-Operative Opioid Prescribing Recommendations Following Shoulder SurgeryOpioid overdose decedent characteristics during COVID-19Exploring the impact of COVID-19 on substance use patterns and service access of street involved individuals in Kingston, Ontario: a qualitative studyLow awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, CanadaNaloxone administration by law enforcement officers in New York State (2015–2020)Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysisDay-to-day impact of COVID-19 and other factors associated with risk of nonfatal overdose among people who use unregulated drugs in five cities in the United States and CanadaAn Education Intervention to Raise Awareness Reduces Self-reported Opioid Overprescribing by Plastic Surgery ResidentsAssessing Clinical Impacts and Attitudes Related to COVID-19 among Residential Substance use Disorder PatientsDifferences in perceived clinical knowledge uptake among health profession students and licensed clinicians receiving buprenorphine waiver training in OregonPerceived Impact of COVID-19 on Prevention, Treatment, Harm Reduction, and Recovery Services for Opioid use Disorder: National Survey of Local Health DepartmentsPreparing for the Future of Medical Education: A Case Series of Traditional and Virtual Clinical Rotations in Addiction Medicine Spanning the COVID PandemicAdvancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration FacilitiesExamination of Factors Affecting Therapeutic Attitude and Empowerment of Perianesthesia Nurses Who Care for Patients With Opioid Use DisorderOpioid-Involved Overdose Vulnerability in Wyoming: Measuring Risk in a Rural EnvironmentEvidenced-Based Opioid Prescribing Recommendations Following Hand and Upper-Extremity SurgeryUltrasound combined with glial cell line-derived neurotrophic factor-loaded microbubbles for the targeted treatment of drug addictionConsensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: A national Delphi studyHarm Reduction Policy Support among Students at Two U.S. UniversitiesA potential paradigm shift in opioid crisis management: The role of pharmacogenomicsBridging the Gap: Dual Fellowship Training in Addiction Medicine and Digestive DiseasesTreatment Experiences Among People Who Use Opioids: A Social Ecological ApproachAssociation of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use DisordersExperimental comparing of lipophilicity of opioid antagonistsUser centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trialDifference in HIV testing behavior by injection status, among users of illicit drugsLearning About and Destigmatizing Substance Use Disorders: a Video-Based Educational Module Using Simulated PatientsA Pilot Program of Interprofessional Care for the Patient with a History of Injectable Drug Use Requiring Intravenous MedicationOptimizing Interdisciplinary Virtual Pain Care and Buprenorphine Initiation During COVID-19: A Quality Improvement StudyPotential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspectivePrediction of Coronavirus Anxiety based on Attachment Styles, Resilience, and Life Expectancy in Drug UsersEditorial Commentary: Multimodal, Opioid-Free Pain Management After Rotator Cuff Repair May Be Safe and Effective, and Decreases the Risk of Drug AbuseLessons for the Opioid Crisis—Integrating Social Determinants of Health Into Clinical CareCollecting Data During the COVID-19 Pandemic: Lessons From an In-Person Survey of People Who Use OpioidsSimilar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical careThe COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 monthsBarriers to Care Experienced by Patients Who Inject Drugs During the COVID-19 Pandemic: A Qualitative AnalysisHarnessing the Power of Social Media to Understand the Impact of COVID-19 on People Who Use Drugs During Lockdown and Social DistancingEmergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care SystemsCoexisting Substance Use Disorder and Chronic Pain During COVID-19Infectious addictions: Geographies of colliding epidemicsMoving Upstream: A Social Emergency Medicine Approach to Opioid Use DisorderThe COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealthPharmacists and opioid use disorder care during COVID ‐19: Call for actionThe Opioid Crisis: A European PerspectiveThe Impact of the COVID-19 Pandemic on the Opioid Epidemic: A Statewide AnalysisComparing mortality from covid-19 to mortality due to overdose: A micromort analysisLow-Threshold Buprenorphine via Community Partnerships and Telemedicine—Case Reports of Expanding Access to Addiction Treatment During COVID-19A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 PandemicCharacterizing Self-Reports of Self-Identified Patient Experiences with Methadone Maintenance Treatment on an Online Community during COVID-19Accounting for confounding by time, early intervention adoption, and time-varying effect modification in the design and analysis of stepped-wedge designs: application to a proposed study design to reduce opioid-related mortalityOpioid use, motivation to quit, and treatment status related to COVID-19: a cross-sectional studyRural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysisDrugs of Abuse and Their Impact on Viral PathogenesisInhibiting endocytosis in CGRP+ nociceptors attenuates inflammatory pain-like behaviorEffects of fentanyl on acute locomotor activity, behavioral sensitization, and contextual reward in female and male ratsTargeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode IslandAmbulance Calls for Substance-Related Issues Before and After COVID-19It Is Time to Implement Primary Prevention in the Workplace to Ameliorate the Ongoing U.S. Opioid EpidemicThe impact of the national stay-at-home order on emergency department visits for suspected opioid overdose during the first wave of the COVID-19 pandemicDoes the Length of Time to Complete an Online Program Matter?Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping ReviewReal-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorderLeveraging Advanced Analytics to Understand the Impact of the COVID-19 Pandemic on Trends in Substance Use DisordersCovalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid PoisoningIdentifying counties at risk of high overdose mortality burden during the emerging fentanyl epidemic in the USA: a predictive statistical modelling studyIdentifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative studyUse of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemicUsing Telecare to Treat Opioid Use Disorder: An Ethnographic Study in New York During COVID-19Investigating and addressing the immediate and long-term consequences of the COVID-19 pandemic on patients with substance use disorders: a scoping review and evidence map protocolEmergency department utilization for mental health conditions before and after the COVID-19 outbreakThe Need for Biochemical Testing for Alcohol in Integrated Addiction Treatment Settings During the Opioid EpidemicA Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 PandemicMethadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and CanadaMandates are not magic bullets: Leveraging context, meaning and relationships to increase meaningful use of prescription monitoring programsImpact of COVID ‐19‐related stress on methamphetamine users in JapanMaintaining treatment and prevention programs for opioid use disorders during the coronavirus disease 2019 pandemicTelemedicine works for treating substance use disorder: The STAR clinic experience during COVID-19Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocolCOVID-19 and the Opioid Epidemic: Two Public Health Emergencies That Intersect With Chronic PainOpioid use disorder and COVID-19Carfentanil and the rise and fall of overdose deaths in the United StatesEvaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorderA cross-sectional analysis of fentanyl analog exposures among living patientsUsing telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode IslandNeuropsychiatric Complications of COVID-19Increased HIV testing in people who use drugs hospitalized in the first wave of the COVID-19 pandemicSubstance Use Disorders and Behavioral Addictions During the COVID-19 Pandemic and COVID-19-Related RestrictionsA Critical Review of the Social and Behavioral Contributions to the Overdose EpidemicAdverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disordersImpact of a shelter-in-place order during the COVID-19 pandemic on the incidence of opioid overdosesAddictions in the COVID-19 era: Current evidence, future perspectives a comprehensive reviewThe Pharmacological War Against and With OpioidsCountermeasures for Preventing and Treating Opioid OverdoseCommentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and CanadaSymptom severity and medication-assisted treatment for individuals with serious mental illness and a history of heroin useRefusals After Prehospital Administration of Naloxone during the COVID-19 PandemicReal-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeuticPerceived risk, attitudes, and behavior of cigarette smokers and nicotine vapers receiving buprenorphine treatment for opioid use disorder during the COVID-19 pandemicHarm reduction in the time of COVID-19: Case study of homelessness and drug use in Dublin, IrelandCOVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United StatesFuture projections of opioid use and cost in patients with chronic osteoarthritis pain in SpainModeling SARS-CoV-2 infection in individuals with opioid use disorder with brain organoidsDeveloping a digital health strategy for people who use drugs: Lessons from COVID-19Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use DisorderIncreases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series StudyHealth(care) in the Crisis: Reflections in Science and Society on Opioid AddictionOpioids and Acute Kidney InjuryOpioid and neuroHIV Comorbidity – Current and Future PerspectivesOpioid Overdose–Related Emergency Department Visits and Accidental Deaths during the COVID-19 PandemicStrategies to maintain persistence of opioid agonist therapy during the novel coronavirus pandemic in TaiwanRevising our attitudes towards agonist medications and their diversion in a time of pandemicCOVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settingsRapid evidence review of harm reduction interventions and messaging for people who inject drugs during pandemic events: implications for the ongoing COVID-19 responseTreatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicineWastewater-based epidemiology pilot study to examine drug use in the Western United StatesOpioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability?Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?Article Commentary: Response to Coronavirus 2019 in Veterans Health Administration Facilities Participating in an Implementation Initiative to Enhance access to Medication for Opioid use DisorderInfectious Diseases and Injection Drug Use: Public Health Burden and ResponseSignal of increased opioid overdose during COVID-19 from emergency medical services dataNo “back to normal” after COVID-19 for our failed drug policiesAddressing Major Health Disparities Related to Coronavirus for People With Behavioral Health Conditions Requires Strength‐Based Capacity Building and Intentional Community PartnershipEnhancement of a Heroin Vaccine through Hapten DeuterationA Community Responds to the COVID-19 Pandemic: a Case Study in Protecting the Health and Human Rights of People Who Use DrugsCOVID-19: The Hidden Impact on Mental Health and Drug AddictionSubstance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and ComplicationsMedication Treatment for Opioid use Disorder and Community Pharmacy: Expanding Care during a National Epidemic and Global PandemicArticle Commentary: COVID-19 and Persons with Substance use Disorders: Inequities and Mitigation StrategiesOpioid substitution therapy with buprenorphine-naloxone during COVID-19 outbreak in India: Sharing our experience and interim standard operating procedure 7 July 2020Volume 173, Issue 1 Page: 59-60 Keywords Computed axial tomography COVID-19 Drug administration Health care Opioid addiction Opioid use disorder Opioids Outpatient clinics Patients Research laboratories ePublished: 2 April 2020 Issue Published: 7 July 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...